Windlas Biotech Share Price

Pharmaceuticals company Windlas Biotech announced Q4FY26 & FY26 results Consolidated Financial Highlights: Quarterly Performance Revenue from Operations: Stood at Rs 2,384.99 million in Q4FY26, representing a YoY increase of 17.66% compared to Rs 2,027.05 million in Q4FY25 and a QoQ increase of 2.32% compared to Rs 2,331.02 million in Q3FY26. Total Income: For Q4FY26 was Rs 2,428.49 million, up 16.96% YoY from Rs 2,076.42 million and up 2.18% QoQ from Rs 2,376.72 million. Profit Before Tax: Stood at Rs 201.61 million in Q4FY26, compared to Rs 208.23 million in Q4FY25 (a decrease of 3.18% YoY) and Rs 199.71 million in Q3FY26 (an increase of 0.95% QoQ). Profit for the Year (Net Profit): In Q4FY26 was Rs 159.90 million, down 1.79% YoY from Rs 162.81 million and up 6.59% QoQ from Rs 150.02 million. Total Comprehensive Income: For Q4FY26 was Rs 160.69 million, compared to Rs 164.40 million in Q4FY25 and Rs 151.75 million in Q3FY26. Earnings Per Share (Basic): For Q4FY26 was Rs 7.58, compared to Rs 7.77 in Q4FY25 and Rs 7.12 in Q3FY26. Annual Performance Revenue from Operations: Grew to Rs 9,040.89 million in FY26, an increase of 18.98% YoY from Rs 7,598.78 million in FY25. Total Income: For FY26 was Rs 9,218.93 million, up 18.51% YoY from Rs 7,778.96 million. Profit Before Tax: For FY26 stood at Rs 869.77 million, representing a 9.05% YoY increase from Rs 797.58 million in FY25. Profit for the Year (Net Profit): Increased by 8.96% YoY to Rs 664.56 million in FY26 from Rs 609.94 million in FY25. Total Comprehensive Income: For the full year FY26 was Rs 665.67 million, compared to Rs 604.45 million in FY25. Standalone Financial Highlights: Quarterly Performance Revenue from Operations: Stood at Rs 2,384.99 million in Q4FY26, compared to Rs 2,027.05 million in Q4FY25 and Rs 2,331.02 million in Q3FY26. Total Income: Was Rs 2,428.97 million in Q4FY26, up 16.98% YoY from Rs 2,076.46 million and up 2.22% QoQ from Rs 2,376.24 million. Profit for the Year (Net Profit): For Q4FY26 was Rs 160.16 million, compared to Rs 162.85 million in Q4FY25 (down 1.65% YoY) and Rs 149.54 million in Q3FY26 (up 7.10% QoQ). Annual Performance Revenue from Operations: Reached Rs 9,040.89 million in FY26, up 18.98% YoY from Rs 7,598.78 million in FY25. Total Income: For FY26 was Rs 9,218.93 million, reflecting an 18.57% YoY increase from Rs 7,775.24 million. Profit for the Year (Net Profit): Grew by 9.54% YoY to Rs 664.35 million in FY26 from Rs 606.49 million in FY25. Business Highlights: Segment Performance: The group operates in only one primarily reportable segment, which is "Pharmaceuticals". Dividend Recommendation: The Board of Directors has recommended a dividend of Rs 6.30 (@126%) per Equity Share of the face value of Rs 5/- each for the financial year ended March 31, 2026. Share Buyback: The company completed a buyback of 470,000 fully paid-up equity shares through the Tender Offer route at a price of Rs 1,000 per share, aggregating to Rs 470,000,000. Following the buyback, the equity share capital stands reduced to 20,636,229 shares. ESOP Allotment: During FY26, the company allotted 146,918 equity shares of Rs 5/- each under its ESOP schemes. The company recorded an ESOP expense of Rs 166.11 million for the year ended March 31, 2026, compared to Rs 24.60 million in FY25. Dissolution of Subsidiary: Windlas Inc., USA, a wholly owned non-operating subsidiary of the company, stood dissolved with effect from March 31, 2026. Joint Venture Update: During the year ended March 31, 2025, Windlas Inc. assigned its 50% share in its Joint Venture, US pharma Windlas LLC, to US Pharma Ltd., and the entity has since ceased to be a joint venture of the company. Audit Opinion: The Statutory Auditors, M/s J C Bhalla & Co, have issued Audit Reports with unmodified opinions on both standalone and consolidated financial results for the quarter and financial year ended March 31, 2026. Result PDF

• Trendlyne
• 2 days 10 hours ago

Pharmaceuticals company Windlas Biotech announced Q3FY26 results Revenue from operations stood at Rs 233.1 crore as against Rs 195.0 crore, a growth of 20% YoY. EBITDA stood at Rs 24.4 crore as against Rs 24.6 crore, with a marginal 1% YoY variation. EBITDA Margin came in at 10.5%. PAT stood at Rs 14.9 crore as against Rs 15.6 crore, declined by 4% YoY. PAT Margin came in at 6.4%. Hitesh Windlass, Managing Director, Windlas Biotech, said: “India’s healthcare budget has crossed Rs 1 lakh crore, signaling stronger support for health infrastructure and affordable treatments. Chronic and sub-chronic therapeutic segments are expanding rapidly due to lifestyle shifts, dietary changes, and rising medicine consumption. Our expertise in fixed-dose combinations and modified-release formulations positions us well to cater to this growing demand and support India’s evolving healthcare needs. The Indian Pharmaceutical Market (IPM) grew 11.8% YoY in Q3FY26, with volume growth of 1.6%. Against this backdrop of modest industry volume growth, Windlas Biotech delivered another strong and consistent quarter, achieving record revenues with YoY growth of 19% in 9MFY26 and 20% in Q3FY26. We remained focused on creating value for our stakeholders. For the first nine months of FY26, the Company reported an earnings per share of Rs 24.02, reflecting a 12% YoY increase. We continue to invest in strengthening our manufacturing infrastructure. Our Injectables and Plant-2 Extn. facilities are paying off with rising contributions to overall growth, and Plant-6 is progressing towards mechanical completion by end of FY26. Looking ahead, we remain focused on creating long-term shareholder value through disciplined execution, diversification of our client base, operational efficiencies, talent development, and expansion across dosage forms.” Komal Gupta, CEO & CFO, Windlas Biotech, said: “Our Highest ever quarterly revenue streak holds steady for 12th quarter. Company reported YoY revenue growth of 19% in 9MFY26 and 20% in Q3FY26, with revenues from operations of Rs 666 crore and Rs 233 crore, respectively. This reflects our disciplined execution and robust performance aligned with stringent quality and regulatory norms. The Budget reaffirms healthcare and pharmaceuticals as strategic national priorities and the company is strategically positioned with our focus on quality manufacturing and scale to leverage estimated sectoral growth opportunities. Generic Formulations CDMO vertical grew 20% in 9MFY26 and 23% in Q3FY26, driven by expanding customer base, increasing wallet share and new product launches. Trade Generics & Institutional vertical grew 18% in 9MFY26 and 7% in Q3FY26. We remain focused on delivering Accessible, Affordable and Authentic medicines across our target geography of tier2 and tier-3 towns in India while also leveraging increased footprint of institutional purchase programs like Jan Aushadhi. Exports vertical grew 29% in 9MFY26 and 36% in Q3FY26 with increased penetration to RoW and semi-regulated markets. Excluding the impact of ESOP expenses, EBITDA for 9MFY26 was Rs 89 crore (13.3%) and PAT Rs 60 crore (9.0%), while Q3FY26 EBITDA stood at Rs 32 crore (13.6%) and PAT Rs 22 crore (9.6%). For 9MFY26 company reported EBITDA of Rs 79 crore and PAT of Rs 50 crore. For Q3FY26 Reported EBITDA was Rs 24 crore and PAT was Rs 15 crore. Our focus is on creating sustainable value for all stakeholders by delivering affordable, highquality medicines. We are committed to strengthening organizational capabilities that align manufacturing infrastructure, product strategy, and high-performing teams. We will continue to deepen customer partnerships, expand our product portfolio, de-risk the business, and reinforce operational and financial discipline.” Result PDF

• Trendlyne
• 3 months 2 weeks ago

Conference Call with Windlas Biotech Management and Analysts on Q1FY26 Performance and Outlook. Listen to the full earnings transcript.

• Trendlyne
• 9 months 1 week ago